All AbMole products are for research use only, cannot be used for human consumption.
Ixabepilone (BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound. Ixabepilone induces cell cycle arrest at the G(2)-M phase transition and subsequent apoptotic cell death of MDA-MB-468 (468) cells. Ixabepilone, on a once every 21-day schedule, is modestly active against metastatic gastric cancer previously treated with a taxane. The days 1-5 every 21 days schedule had a more favorable safety profile but no activity. The results of this study suggest that once every 21-day ixabepilone schedule should be pursued further in untreated gastric or gastroesophageal adenocarcinoma patients. Ixabepilone has demonstrated activity in patients with chemotherapy-naive metastatic HRPC. Major toxicities were neutropenia and neuropathy. Further testing to define its activity relative to standard therapy is warranted.
Molecular Weight | 506.7 |
Formula | C27H42N2O5S |
CAS Number | 219989-84-1 |
Solubility (25°C) | DMSO |
Storage | 2-8°C, protect from light |
Related Microtubule Products |
---|
CCB02
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. |
Lisavanbulin
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862). |
20-O-Demethyl-AP3
20-O-Demethyl-AP3 is a minor metabolite of Ansamitocin P-3. |
Lisavanbulin dihydrochloride
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862). |
Paclitaxel-d5
Paclitaxel-d5 |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.